Literature DB >> 17314230

Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection.

Dong Sung An1, Betty Poon, Raphael Ho Tsong Fang, Kees Weijer, Bianca Blom, Hergen Spits, Irvin S Y Chen, Christel H Uittenbogaart.   

Abstract

The goal of this study was to develop a small-animal model to study human immunodeficiency virus type 1 (HIV-1) pathogenesis in blood and primary and secondary lymphoid organs. Rag2(-/-)gamma(c)(-/-) mice that are neonatally injected with human CD34(+) cells develop a functional human immune system (HIS), with human hematopoietic cells being found in the thymuses, peripheral blood, spleens, and bone marrow of the animals (hereafter these animals are referred to as HIS-Rag2(-/-)gamma(c)(-/-) mice). HIS-Rag2(-/-)gamma(c)(-/-) mice were infected with small amounts of CCR5-tropic HIV-1. Viral replication and immunophenotypic changes in the human cells in peripheral blood and lymphoid organs were examined. The productive infection of human cells in peripheral blood, thymus and spleen tissue, and bone marrow was detected. Ratios of CD4(+) T cells to CD8(+) T cells in the infected animals declined. Although no specific anti-HIV-1 immune responses were detected, immunoglobulin M (IgM) and IgG antibodies to an unidentified fetal calf serum protein present in the virus preparation were found in the inoculated animals. Thus, we have shown that the HIS-Rag2(-/-)gamma(c)(-/-) mouse model can be used for infection with low doses of CCR5-tropic HIV-1, which is most commonly transmitted during primary infections. HIS-Rag2(-/-)gamma(c)(-/-) mice can serve as a small-animal model for investigating HIV-1 pathogenesis and testing potential HIV-1 therapies, and studies with this model may replace some long and costly studies with nonhuman primates.

Entities:  

Mesh:

Year:  2007        PMID: 17314230      PMCID: PMC1865603          DOI: 10.1128/CVI.00403-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  30 in total

Review 1.  Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experiments.

Authors:  Koen K A Van Rompay
Journal:  AIDS Rev       Date:  2005 Apr-Jun       Impact factor: 2.500

2.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice.

Authors:  Fumihiko Ishikawa; Masaki Yasukawa; Bonnie Lyons; Shuro Yoshida; Toshihiro Miyamoto; Goichi Yoshimoto; Takeshi Watanabe; Koichi Akashi; Leonard D Shultz; Mine Harada
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

3.  Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice.

Authors:  Stefan Baenziger; Roxane Tussiwand; Erika Schlaepfer; Luca Mazzucchelli; Mathias Heikenwalder; Michael O Kurrer; Silvia Behnke; Joachim Frey; Annette Oxenius; Helen Joller; Adriano Aguzzi; Markus G Manz; Roberto F Speck
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-12       Impact factor: 11.205

4.  Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection.

Authors:  J Browning; J W Horner; M Pettoello-Mantovani; C Raker; S Yurasov; R A DePinho; H Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

5.  Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.

Authors:  B Poon; J F Hsu; V Gudeman; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 6.  Experimental models to study development and function of the human immune system in vivo.

Authors:  Nicolas Legrand; Kees Weijer; Hergen Spits
Journal:  J Immunol       Date:  2006-02-15       Impact factor: 5.422

7.  Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage.

Authors:  A Mörner; A Björndal; J Albert; V N Kewalramani; D R Littman; R Inoue; R Thorstensson; E M Fenyö; E Björling
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/- gammac-/- mice: functional inactivation of p53 in developing T cells.

Authors:  Ramon Gimeno; Kees Weijer; Arie Voordouw; Christel H Uittenbogaart; Nicolas Legrand; Nuno L Alves; Erwin Wijnands; Bianca Blom; Hergen Spits
Journal:  Blood       Date:  2004-08-19       Impact factor: 22.113

9.  Disturbed CD4+ T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors.

Authors:  S Sawada; K Gowrishankar; R Kitamura; M Suzuki; G Suzuki; S Tahara; A Koito
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

10.  PIM1 reconstitutes thymus cellularity in interleukin 7- and common gamma chain-mutant mice and permits thymocyte maturation in Rag- but not CD3gamma-deficient mice.

Authors:  H Jacobs; P Krimpenfort; M Haks; J Allen; B Blom; C Démollière; A Kruisbeek; H Spits; A Berns
Journal:  J Exp Med       Date:  1999-10-18       Impact factor: 14.307

View more
  39 in total

Review 1.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

2.  A doxycycline-dependent human immunodeficiency virus type 1 replicates in vivo without inducing CD4+ T-cell depletion.

Authors:  Nicolas Legrand; Gisela J van der Velden; Raphaël Ho Tsong Fang; Marc Douaisi; Kees Weijer; Atze T Das; Bianca Blom; Christel H Uittenbogaart; Ben Berkhout; Mireille Centlivre
Journal:  J Gen Virol       Date:  2012-05-30       Impact factor: 3.891

Review 3.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

4.  RAG2-/- gamma(c)-/- mice transplanted with CD34+ cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus.

Authors:  Ursula Hofer; Stefan Baenziger; Mathias Heikenwalder; Erika Schlaepfer; Nadine Gehre; Stephan Regenass; Thomas Brunner; Roberto F Speck
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

5.  Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice.

Authors:  Kaori Sango; Aviva Joseph; Mahesh Patel; Kristin Osiecki; Monica Dutta; Harris Goldstein
Journal:  AIDS Res Hum Retroviruses       Date:  2010-07       Impact factor: 2.205

6.  Experimental Adaptive Evolution of Simian Immunodeficiency Virus SIVcpz to Pandemic Human Immunodeficiency Virus Type 1 by Using a Humanized Mouse Model.

Authors:  Kei Sato; Naoko Misawa; Junko S Takeuchi; Tomoko Kobayashi; Taisuke Izumi; Hirofumi Aso; Shumpei Nagaoka; Keisuke Yamamoto; Izumi Kimura; Yoriyuki Konno; Yusuke Nakano; Yoshio Koyanagi
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

Review 7.  Novel humanized murine models for HIV research.

Authors:  Paul W Denton; J Victor Garcia
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

8.  Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice.

Authors:  Bradford K Berges; Sarah R Akkina; Joy M Folkvord; Elizabeth Connick; Ramesh Akkina
Journal:  Virology       Date:  2008-01-18       Impact factor: 3.616

Review 9.  The utilization of humanized mouse models for the study of human retroviral infections.

Authors:  Rachel Van Duyne; Caitlin Pedati; Irene Guendel; Lawrence Carpio; Kylene Kehn-Hall; Mohammed Saifuddin; Fatah Kashanchi
Journal:  Retrovirology       Date:  2009-08-12       Impact factor: 4.602

10.  Priming of protective T cell responses against virus-induced tumors in mice with human immune system components.

Authors:  Till Strowig; Cagan Gurer; Alexander Ploss; Yi-Fang Liu; Frida Arrey; Junji Sashihara; Gloria Koo; Charles M Rice; James W Young; Amy Chadburn; Jeffrey I Cohen; Christian Münz
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.